Clinical trial · Interventional
The Efficacy of Multisession Mindful Breathing in Symptom Reduction Among Patients With Advanced Cancers
The Efficacy of Multisession Mindful Breathing in Symptom Reduction Among Patients: A Randomised Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to determine the efficacy of multisession mindful breathing in reducing symptoms among patients with advanced cancer. Adult patients with advanced cancer will be assessed using Edmonton Symptom Assessment System (ESAS) scoring system. Patients who scored ≥4 in at least two or more components in ESAS will be recruited and randomly assigned to either 4 daily-session of 30-minute mindful breathing and standard care or standard care alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mindful breathing | Behavioral | — | UNRESOLVED |
| Standard care (control) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Patients will receive standard care plus daily sessions of 30-minute mindful breathing for four consecutive days
- interventionNames
- Behavioral: Mindful breathing
- Other: Standard care (control)
- type
- SHAM_COMPARATOR
- label
- Control
- description
- Patients will only receive standard care.
- interventionNames
- Other: Standard care (control)
Primary outcomes (1)
- measure
- Total score of ESAS
- timeFrame
- 30 muinutes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ongoing stage IIII-IV cancer, and a score of four or more in at least two components Exclusion Criteria: * impaired cognition or conscious level, as well as psychiatric illnesses that prevent them from giving informed consent or participating fully in the study
References
Publications (3)
- BACKGROUNDChang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000 May 1;88(9):2164-71. doi: 10.1002/(sici)1097-0142(20000501)88:93.0.co;2-5. PMID 10813730
- RESULTBruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991 Summer;7(2):6-9. PMID 1714502
- DERIVEDTung YZ, Ng DLC, Lai NZ, Ang CM, Lim PK, Zainuddin SI, Lam CL, Loh EC, Chai CS, Tan SB. Symptom reduction in advanced cancer from multi-session mindful breathing: randomised controlled study. BMJ Support Palliat Care. 2026 Apr 28;16(3):711-719. doi: 10.1136/spcare-2024-005086. PMID 39965903